Abstract
Background: Diffuse intrinsic pontine gliomas represent a unique subtype of primary brain tumors occuring in a specific location and age. Their growth demonstrates early invasion and, following diagnosis, rapid growth not responsive to common therapies. Until recently, the genetic and cellular basis of these tumors was unknown. Genetic evidence implicates mutations in the histone genes in the origin of these tumors.
Methods: Surgical biopsies performed on selected patients have resulted in the establishment of anatomically accurate mouse models that have been used to examine patterns of growth and response to new therapeutic agents. Results: Human derived pontine glioma models recapitulate the invasive patterns of growth. The grade of the original tumor affects the latency of tumor growth after implantation. Conclusion: The use of human-derived xenograft models allows for improved pre-clinical testing of new therapeutic targets in a tumor- and organ-specific manner.Keywords: Bioluminescent imaging, brainstem glioma, DIPG, H3K27M mutation, infiltrating astrocytoma, xenograft model.
Current Neuropharmacology
Title:Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas
Volume: 15 Issue: 1
Author(s): Rintaro Hashizume and Nalin Gupta
Affiliation:
Keywords: Bioluminescent imaging, brainstem glioma, DIPG, H3K27M mutation, infiltrating astrocytoma, xenograft model.
Abstract: Background: Diffuse intrinsic pontine gliomas represent a unique subtype of primary brain tumors occuring in a specific location and age. Their growth demonstrates early invasion and, following diagnosis, rapid growth not responsive to common therapies. Until recently, the genetic and cellular basis of these tumors was unknown. Genetic evidence implicates mutations in the histone genes in the origin of these tumors.
Methods: Surgical biopsies performed on selected patients have resulted in the establishment of anatomically accurate mouse models that have been used to examine patterns of growth and response to new therapeutic agents. Results: Human derived pontine glioma models recapitulate the invasive patterns of growth. The grade of the original tumor affects the latency of tumor growth after implantation. Conclusion: The use of human-derived xenograft models allows for improved pre-clinical testing of new therapeutic targets in a tumor- and organ-specific manner.Export Options
About this article
Cite this article as:
Hashizume Rintaro and Gupta Nalin, Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas, Current Neuropharmacology 2017; 15 (1) . https://dx.doi.org/10.2174/1570159X14666160523144117
DOI https://dx.doi.org/10.2174/1570159X14666160523144117 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in paediatric and adult brain cancers: emerging targets and treatments
Brain tumors are the most common solid tumors affecting children and adolescents, with up to 5,000 children diagnosed per year. Pediatric brain tumors, because of their location, are often untreatable and their clinical management can cause significant long-term impairment to intellectual and neurological function with epilepsy and neurodegeneration. Other than ...read more
Emotion (Dys)regulation: An integration of Pharmacological, Neurobiological, and Psychological Frameworks
Emotion regulation is a critical aspect of mental well-being and interpersonal relationships. To fully understand and effectively address emotion regulation, an integrative approach that considers pharmacological, neurobiological, and psychological frameworks is essential. Pharmacological interventions, such as medications targeting neurotransmitter imbalances, can play a significant role in managing emotional dysregulation. Understanding ...read more
Enhancing Neuropharmacology with Home Cage Monitoring, Advanced Delivery and Stimulation Technologies, and Artificial Intelligence
Home cage monitoring (HCM) technologies have revolutionized neuropharmacological research by enabling continuous, non-invasive observation of rodents in their natural environments. Complementary advancements such as 24/7 continuous drug delivery systems (e.g., implantable pumps) and wireless neurostimulation methods—including optogenetics—offer precise methods for modulating neural activity and administering pharmacological agents without disrupting the ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets Retinal Ganglion Cell Gene Therapy and Visual System Repair
Current Gene Therapy Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Recent Patents in Oncolytic Virotherapy
Recent Patents on Biotechnology Reality Check: Cancer Stem Cell Route to Cancer
Current Biotechnology Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy
Current Drug Metabolism Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Analysis of miRNAs Targeting 3’UTR of H2AFX Gene: a General <i>in Silico</i> Approach
MicroRNA Plant Coumestans: Recent Advances and Future Perspectives in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Modern Treatments for Gliomas Improve Outcome
Current Cancer Therapy Reviews Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets New Vessel Formation in the Central Nervous System During Tumor Growth, Vascular Malformations, and Moyamoya
Current Neurovascular Research Alkaloid-Metal Based Anticancer Agents
Current Topics in Medicinal Chemistry Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Melanoma Differentiation Associated Gene-7 (mda-7)/ Interleukin-24 (IL-24), mda-7/IL-24: Current Perspectives on a Unique Member of the IL-10 Family of Cytokines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Molecular Targets in the Treatment of NSCLC
Current Pharmaceutical Design A Novel Botulinum Toxin TAT-EGFP-HCS Fusion Protein Capable of Specific Delivery Through the Blood-brain Barrier to the Central Nervous System
CNS & Neurological Disorders - Drug Targets